Composition and method of treating dopamine deficiency in brain tissue

Claim 3

The method of claim 1 wherein the Compound (B) is L-α-hydrazino-α-methyl-3,4-dihydroxyphenyl propionic acid. .[.3. The method of claim 1 wherein the Compound (B) is

Claim 4

α-hydrazino-3,4-dihydroxyphenyl propionic acid..]. 4. A method of increasing the dopamine content in the bran tissue of an animal which comprises administering to the animal from about 0.05 to about 300 mg./kg. of body weight of a composition containing a Compound (A) selected from the group consisting of L-dopa and a pharmaceutically acceptable non-toxic salt thereof and a Compound (B) selected from the group consisting of L-α-hydrazino-α-lower alkyl-3,4-dihydroxyphenyl propionic acid .[.and α-hydrazino-3,4-dihydroxyphenyl propionic acid.]. and a pharmaceutically acceptable non-toxic salt thereof, wherein the ratio of

Claim 5

α-hydrazino-3,4-dihydroxyphenyl propionic acid..]. 4. A method of increasing the dopamine content in the bran tissue of an animal which comprises administering to the animal from about 0.05 to about 300 mg./kg. of body weight of a composition containing a Compound (A) selected from the group consisting of L-dopa and a pharmaceutically acceptable non-toxic salt thereof and a Compound (B) selected from the group consisting of L-α-hydrazino-α-lower alkyl-3,4-dihydroxyphenyl propionic acid .[.and α-hydrazino-3,4-dihydroxyphenyl propionic acid.]. and a pharmaceutically acceptable non-toxic salt thereof, wherein the ratio of

Claim 6

Compound (A) to Compound (B) is from about 0.05 to about 500. 5. The method of claim 4 wherein the Compound (B) is L-α-hydrazino-α-methyl-3,4-dihydroxyphenyl propionic acid. .[.6. The method of claim 4 wherein the Compound (B) is

Claim 7

α-hydrazino-3,4-dihydroxyphenyl propionic acid..]. 7. The method of

Claim 8

α-hydrazino-3,4-dihydroxyphenyl propionic acid..]. 7. The method of

Claim 9

claim 4 wherein the compounds are administered orally. 8. The method of

Claim 10

claim 4 wherein the compounds are administered sequentially. 9. The method

Claim 11

of claim 4 wherein the compounds are administered simultaneously. 10. The method of claim 4 wherein the ratio of Compound (A) to Compound (B) is

Claim 12

from about 0.5 to about 50. 11. The method of claim 4 wherein the ratio of

Claim 13

Compound (A) to Compound (B) is from about 1 to about 30. 12. A pharmaceutical composition comprising a Compound (A) selected from the group consisting of L-dopa and a pharmaceutically acceptable non-toxic salt thereof and a Compound (B) selected from the group consisting of L-α-hydrazino-α-lower alkyl-3,4-dihydroxyphenyl propionic acid .[.and α-hydrazino-3,4-dihydroxyphenyl propionic acid.]. and a pharmaceutically acceptable non-toxic salt thereof, wherein the ratio of

Claim 14

Compound (A) to Compound (B) is from about 1 to about 30. 12. A pharmaceutical composition comprising a Compound (A) selected from the group consisting of L-dopa and a pharmaceutically acceptable non-toxic salt thereof and a Compound (B) selected from the group consisting of L-α-hydrazino-α-lower alkyl-3,4-dihydroxyphenyl propionic acid .[.and α-hydrazino-3,4-dihydroxyphenyl propionic acid.]. and a pharmaceutically acceptable non-toxic salt thereof, wherein the ratio of

Claim 15

Compound (A) to Compound (B) is from about 0.05 to about 500. 13. The pharmaceutical composition of claim 12 wherein the ratio of Compound (A)

Claim 16

to Compound (B) is from about 0.5 to about 50. 14. The pharmaceutical composition of claim 12 wherein the ratio of Compound (A) to Compound (B) is from about 1 to about 30. .Iadd. 15. The pharmaceutical composition of claim 12 wherein the Compound (B) is L-α-hydrazino-α-methyl-3,4-dihydroxyphenyl propionic acid..Iaddend.